Published in Br J Pharmacol on January 13, 2015
How computer simulations of the human heart can improve anti-arrhythmia therapy. J Physiol (2016) 0.77
Chinese innovation in cardiovascular drug discovery. Br J Pharmacol (2015) 0.75
The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43
Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol (1977) 12.38
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 11.62
Impulses and Physiological States in Theoretical Models of Nerve Membrane. Biophys J (1961) 9.99
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
A modification of the Hodgkin--Huxley equations applicable to Purkinje fibre action and pace-maker potentials. J Physiol (1962) 8.72
HERG, a human inward rectifier in the voltage-gated potassium channel family. Science (1995) 7.26
A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res (1994) 6.93
hERG potassium channels and cardiac arrhythmia. Nature (2006) 6.63
The inward rectification mechanism of the HERG cardiac potassium channel. Nature (1996) 6.29
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Reconstruction of the action potential of ventricular myocardial fibres. J Physiol (1977) 5.56
Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta (1977) 5.26
A model for human ventricular tissue. Am J Physiol Heart Circ Physiol (2003) 4.91
A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophys J (2004) 3.72
Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol (1998) 3.41
Alternans and spiral breakup in a human ventricular tissue model. Am J Physiol Heart Circ Physiol (2006) 3.36
Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol (2011) 3.21
Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature (1960) 3.14
Ionic current basis of electrocardiographic waveforms: a model study. Circ Res (2002) 3.09
The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol (2013) 3.03
Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model. Circulation (2004) 2.83
Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation (2005) 2.77
Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation (2002) 2.49
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res (2011) 2.41
Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J (1984) 2.33
A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ Res (1994) 2.26
An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol (2010) 2.23
Principles: receptor theory in pharmacology. Trends Pharmacol Sci (2004) 2.18
Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 2.11
Models of cardiac tissue electrophysiology: progress, challenges and open questions. Prog Biophys Mol Biol (2010) 1.92
A computational model of the human left-ventricular epicardial myocyte. Biophys J (2004) 1.88
A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. Sci Transl Med (2011) 1.78
Fast sodium current in cardiac muscle. A quantitative description. Biophys J (1980) 1.74
Kinetic properties of the cardiac L-type Ca2+ channel and its role in myocyte electrophysiology: a theoretical investigation. Biophys J (2006) 1.71
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol (2006) 1.70
Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys (2006) 1.60
Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res (2005) 1.58
Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome. Circ Res (2008) 1.55
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. Am J Physiol Heart Circ Physiol (2000) 1.50
Systems biology and the virtual physiological human. Mol Syst Biol (2009) 1.48
A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential. Proc Natl Acad Sci U S A (2009) 1.43
Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol (1999) 1.34
Phasic ion channel blockade. A kinetic model and parameter estimation procedure. Mol Pharmacol (1985) 1.33
Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions. Phys Med Biol (2006) 1.30
Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol (2012) 1.26
Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol (2006) 1.23
Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation (1991) 1.23
The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol (2004) 1.23
Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism. Cardiovasc Res (2007) 1.22
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Contributions of HERG K+ current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol (2007) 1.13
Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res (2005) 1.13
Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations. Philos Trans A Math Phys Eng Sci (2010) 1.11
Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther (1989) 1.07
Lidocaine blockade of continuously and transiently accessible sites in cardiac sodium channels. J Mol Cell Cardiol (1991) 1.07
Evolution and pharmacological modulation of the arrhythmogenic wave dynamics in canine pulmonary vein model. Europace (2014) 1.05
Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. Circ Res (2013) 1.04
Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation (2011) 1.03
A mathematical model of action potentials of mouse sinoatrial node cells with molecular bases. Am J Physiol Heart Circ Physiol (2011) 0.98
Effects of Na(+) and K(+) channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue. Am J Physiol Heart Circ Physiol (2005) 0.97
hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment. J Cardiovasc Electrophysiol (2013) 0.96
Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods (2005) 0.96
A brief history of tissue models for cardiac electrophysiology. IEEE Trans Biomed Eng (2014) 0.96
Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol (2008) 0.96
Proarrhythmic response to potassium channel blockade. Numerical studies of polymorphic tachyarrhythmias. Circulation (1995) 0.95
Effects of the antiarrhythmic drug dofetilide on transmural dispersion of repolarization in ventriculum. A computer modeling study. IEEE Trans Biomed Eng (2010) 0.95
Theoretical characterization of ion channel blockade. Competitive binding to periodically accessible receptors. Biophys J (1987) 0.92
In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr Pharm Biotechnol (2008) 0.92
Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol (2006) 0.91
Multi-scale electrophysiology modeling: from atom to organ. J Gen Physiol (2010) 0.90
Ligand binding to transiently accessible sites: mechanisms for varying apparent binding rates. J Theor Biol (1987) 0.89
In silico study of action potential and QT interval shortening due to loss of inactivation of the cardiac rapid delayed rectifier potassium current. Biochem Biophys Res Commun (2004) 0.88
Frequency-dependent effects of various IKr blockers on cardiac action potential duration in a human atrial model. Am J Physiol Heart Circ Physiol (2007) 0.88
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome. PLoS Comput Biol (2011) 0.87
Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. Cardiovasc Res (2009) 0.87
Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol (1996) 0.87
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol (2004) 0.86
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. J Mol Cell Cardiol (2014) 0.86
Repolarisation and vulnerability to re-entry in the human heart with short QT syndrome arising from KCNQ1 mutation--a simulation study. Prog Biophys Mol Biol (2007) 0.86
Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. Biophys J (1996) 0.85
Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms. Europace (2012) 0.84
Effects of late sodium current enhancement during LQT-related arrhythmias. A simulation study. Conf Proc IEEE Eng Med Biol Soc (2010) 0.84
In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics. Biophys J (2012) 0.84
What happens when cardiac Na channels lose their function? 1--numerical studies of the vulnerable period in tissue expressing mutant channels. Cardiovasc Res (2003) 0.84
Bifurcation theory and cardiac arrhythmias. Am J Cardiovasc Dis (2013) 0.83
Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus. Virology (2014) 0.83
Markov models of use-dependence and reverse use-dependence during the mouse cardiac action potential. PLoS One (2012) 0.82
Continuum molecular simulation of large conformational changes during ion-channel gating. PLoS One (2011) 0.81
What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. Cardiovasc Res (2003) 0.81
Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations. Br J Pharmacol (2012) 0.80
Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J Cardiovasc Pharmacol (2011) 0.80
Interaction of specialized cardiac conduction system with antiarrhythmic drugs: a simulation study. IEEE Trans Biomed Eng (2011) 0.80
Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study. Ann Biomed Eng (2005) 0.79
Kinetics of drug interaction with the Kv11.1 potassium channel. Mol Pharmacol (2014) 0.78
New aspects of vulnerability in heterogeneous models of ventricular wall and its modulation by loss of cardiac sodium channel function. Med Biol Eng Comput (2005) 0.76
Potassium channel blockade amplifies cardiac instability numerical studies of torsades de pointes. Indian J Physiol Pharmacol (1994) 0.76
Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. IEEE Trans Biomed Eng (2003) 0.75
Acute amiodarone promotes drift and early termination of spiral wave re-entry. Heart Vessels (2010) 0.75
Multiview stereo and silhouette fusion via minimizing generalized reprojection error. Image Vis Comput (2015) 0.75
A Mathematical Model of the Mouse Atrial Myocyte With Inter-Atrial Electrophysiological Heterogeneity. Front Physiol (2020) 0.75
Computational Cardiac Modeling Reveals Mechanisms of Ventricular Arrhythmogenesis in Long QT Syndrome Type 8: CACNA1C R858H Mutation Linked to Ventricular Fibrillation. Front Physiol (2017) 0.75
A composite visualization method for electrophysiology-morphous merging of human heart. Biomed Eng Online (2017) 0.75